Keenova Therapeutics Financial Results Summary for Third Quarter 2025
Keenova Therapeutics, formerly Mallinckrodt plc, has reported impressive financial results for the third quarter of 2025. The company achieved net sales of $753.1 million, reflecting a 49% growth compared to the previous year. This growth is notably driven by the rising demand for Acthar Gel, a key product in the company’s therapeutic portfolio.
Key Financial Highlights
In particular, the third quarter saw substantial contributions from both the Specialty Brands segment and the Generics segment. The Specialty Brands generated $416 million in net sales, primarily from Acthar Gel and Xiaflex, while the Generics segment reported $337.1 million.
Keenova is also pleased to announce an expectation of fourth-quarter net sales ranging between $485 million to $505 million and an adjusted EBITDA of $155 million to $165 million for its products.
Recent Developments in Keenova's Business
Following the merger with Endo, Keenova has acquired a broader portfolio, enhancing its operational capabilities. CEO Siggi Olafsson expressed excitement about the company’s future, emphasizing the strong brand momentum of Acthar Gel and the initiation of a clinical program for XIAFLEX targeting hammertoe.
Guidance for the Future
Keenova has raised its full-year growth guidance for Acthar Gel to an impressive forecast of 30% to 35%. This reflects robust demand and a growing prescriber base, which is expected to sustain the brand's growth trajectory.
Segment Operating Performance
The financial results for the three months ending September 26, 2025, include two months of performance from Endo's operations. The company categorized its business into three reportable segments:
- Specialty Brands: Focuses on autoimmune and rare diseases, including products like Acthar Gel and Xiaflex.
- Generics: Comprises various products in the generics market.
- Sterile Injectables: Encompasses a range of sterile injectable products.
Third Quarter Financial Performance Breakdown
For the third quarter of 2025, the company reported a net loss of $291.1 million, primarily influenced by merger-related expenses. Despite the net loss, the adjusted EBITDA was calculated at $111.3 million, which indicates operational strength in certain segments.
Long-Term Growth Strategy
Keenova remains on course to realize significant synergies post-merger, estimated at $75 million within the first year and a long-term target exceeding $150 million. Management is optimistic about integrating its operations, enhancing efficiencies, and increasing shareholder value.
Investors Conference Call
The company will conduct a conference call to discuss these results further. Investors are encouraged to join the call to hear more about Keenova's strategic plans and future expectations.
About Keenova Therapeutics
As a global leader in developing and manufacturing branded therapeutics, Keenova is dedicated to addressing unmet medical needs across various therapeutic areas. The company's commitment is reflected in its broad range of products geared towards improving patient lives.
Frequently Asked Questions
What are Keenova's latest financial results?
Keenova reported net sales of $753.1 million in Q3 2025, a 49% increase year-over-year.
What is the outlook for Acthar Gel?
The company has raised its full-year growth guidance for Acthar Gel to 30%-35% growth.
How did the merger with Endo impact performance?
The merger contributed to an expanded product portfolio and resulted in enhanced sales, with notable contributions from both Specialty Brands and Generics segments.
What is the expected adjusted EBITDA for the fourth quarter of 2025?
Keenova projects an adjusted EBITDA of $155 million to $165 million for the fourth quarter of 2025.
What is Keenova's long-term strategy post-merger?
Keenova aims to achieve operational synergies of $75 million within the first year post-merger and plans to exceed $150 million in annual synergies by year three through integration and efficiency improvements.
